Tenax Therapeutics Financials

$8.9 M

Mkt cap, 25-Apr-2018
Net income (Q2, 2017)3 M
Cash, 30-Jun-20172.2 M

Revenue/Financials

Income Statement

Annual

USDFY, 2014FY, 2015FY, 2016

Revenue

158.9 k49.3 k

Revenue growth, %

(69%)(100%)

Cost of goods sold

Gross profit

R&D expense

6.5 m

General and administrative expense

3.9 m

Operating expense total

10.4 m

EBIT

(16.6 m)(14.8 m)(52.7 m)

EBIT margin, %

(10452%)(30063%)

Interest expense

2.2 m49.1 k

Income tax expense

Net Income

(19.5 m)(14.1 m)(43.9 m)

Quarterly

USDQ1, 2016Q2, 2016Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

R&D expense

1.7 m2.5 m3.9 m3.4 m3.2 m2.1 m1.2 m

General and administrative expense

1.4 m1.2 m1.8 m1.2 m1.3 m1.4 m1.8 m

Operating expense total

3.1 m3.7 m5.7 m4.7 m4.5 m3.5 m3 m

Interest expense

1.1 k404

Net Income

3 m3.5 m5.4 m4.6 m4.3 m3.3 m3 m

Balance Sheet

Annual

USDFY, 2014FY, 2015FY, 2016

Cash

58.3 m7.9 m10 m

Accounts Receivable

36.4 k76.5 k72.6 k

Current Assets

59 m17.5 m13.6 m

PP&E

124.4 k50.3 k19.1 k

Goodwill

11.3 m11.3 m

Total Assets

93.4 m82.9 m23.3 m

Accounts Payable

411.1 k1.2 m727.6 k

Current Liabilities

2.6 m4.5 m6.2 m

Long-term debt

346.9 k100.2 k

Total Debt

346.9 k100.2 k

Total Liabilities

6.2 m

Additional Paid-in Capital

219.5 m221.1 m221.8 m

Retained Earnings

(136.6 m)(150.7 m)(204.7 m)

Total Equity

82.9 m70.4 m17.1 m

Debt to Equity Ratio

0 x0 x

Debt to Assets Ratio

0 x0 x

Financial Leverage

1.1 x1.2 x1.4 x

Quarterly

USDQ1, 2016Q2, 2016Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

3.7 m5.1 m3.3 m1.9 m722.2 k7 m2.2 m

Accounts Receivable

98.6 k86.3 k49.3 k24.6 k72.6 k24.6 k24.6 k

Current Assets

21.6 m21.9 m16.1 m10.2 m7.7 m12.8 m9 m

PP&E

54.4 k42.1 k34 k29 k23.5 k18.3 k14.9 k

Goodwill

11.3 m11.3 m11.3 m11.3 m11.3 m

Total Assets

78.6 m75.5 m69.5 m64.1 m59.7 m19.2 m13.4 m

Accounts Payable

680.7 k521.2 k2.1 m1.5 m1.4 m1.4 m434.2 k

Current Liabilities

3.3 m3.6 m6.2 m5.3 m5.1 m5 m2.2 m

Long-term debt

48.4 k

Total Debt

48.4 k

Total Liabilities

11.2 m11.5 m14.2 m13.2 m13 m5 m2.2 m

Additional Paid-in Capital

221.1 m221.2 m221.4 m221.5 m221.7 m222.1 m222.2 m

Retained Earnings

(153.7 m)(157.2 m)(166.1 m)(170.7 m)(175 m)(207.9 m)(210.9 m)

Total Equity

67.4 m63.9 m55.3 m50.9 m46.7 m14.1 m11.3 m

Financial Leverage

1.2 x1.2 x1.3 x1.3 x1.3 x1.4 x1.2 x

Cash Flow

Annual

USDFY, 2014FY, 2015FY, 2016

Net Income

(19.5 m)(14.1 m)(10.1 m)

Depreciation and Amortization

150.5 k148.1 k31.2 k

Inventories

Cash From Operating Activities

(9.3 m)(9.7 m)(9 m)

Purchases of PP&E

(9.8 k)(4.2 k)(16.7 k)

Cash From Investing Activities

(147 k)(40.9 m)4.8 m

Cash From Financing Activities

66.9 m280.6 k(100.2 k)

Interest Paid

1.5 k

Quarterly

USDQ1, 2016Q2, 2016Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

(3 m)(6.6 m)(5.4 m)(10 m)(14.3 m)(3.3 m)6.3 m

Depreciation and Amortization

12.7 k25 k4.6 k9.7 k14.5 k4 k7.5 k

Cash From Operating Activities

(3.8 m)(6.5 m)(3.3 m)(8.5 m)(12.8 m)(4 m)(9.6 m)

Purchases of PP&E

(16.7 k)(16.7 k)(2.9 k)(2.9 k)(2.9 k)(3.3 k)(3.3 k)

Cash From Investing Activities

(380.9 k)3.8 m2.9 m6.8 m9.8 m1.1 m1.9 m

Cash From Financing Activities

(51.8 k)(100.2 k)

Interest Paid

1.1 k1.5 k

Ratios

USDY, 2017

Financial Leverage

1.2 x
Report incorrect company information

Operating Metrics

FY, 2016

Patents Issued

7

Phase III Trials Products

1

Preclinical Phase Products

1
Report incorrect company information